ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FSD Pharma Announces Termination of FSD-201 Phase 2 Clinical Trial
August 25, 2021FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "FSD") announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide ("PEA"), or FSD-201, for use in treating COVID-19. -
Therapix Biosciences Terminates FSD Acquisition Letter of Intent
December 24, 2018Therapix Biosciences, a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments..... -
M Pharmaceutical to develop new topical drug product for FSD
January 17, 2017Canadian-headquartered M Pharmaceutical has announced plans to continue advancing the development of a topical drug product as part of its planned acquisition of 40 J's.
Pharma Sources Insight January 2025
